U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Showing 1 - 10 of 171 results

Status:
US Approved Rx (2020)
First approved in 2020

Class (Stereo):
CHEMICAL (RACEMIC)


Conditions:

Amisulpride, a benzamide derivative, shows a unique therapeutic profile being atypical antipsychotic. At low doses, it enhances dopaminergic neurotransmission by preferentially blocking presynaptic dopamine D2/D3 autoreceptors. At higher doses, amisu...
Status:
US Approved Rx (2016)
First approved in 2016

Class (Stereo):
CHEMICAL (ACHIRAL)



Pimavanserin, marketed under the trade name Nuplazid, a non-dopaminergic atypical antipsychotic developed by Acadia Pharmaceuticals is the first and only medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of hallucin...
Status:
US Approved Rx (2025)
First approved in 2015

Class (Stereo):
CHEMICAL (ACHIRAL)



Brexpiprazole is a novel D2 dopamine and serotonin 1A partial agonist, called serotonin-dopamine activity modulator (SDAM), and a potent antagonist of serotonin 2A receptors, noradrenergic alpha 1B and 2C receptors. Brexpiprazole is approved for the ...
Status:
US Approved Rx (2015)
First approved in 2015

Class (Stereo):
CHEMICAL (ABSOLUTE)



Cariprazine is an antipsychotic approved by FDA for the treatment of schizophrenia and bipolar I disorder. The drug has a unique clinical action which is explained by its ability to act on dopamine D3 receptors. Pharmacology studies revealed that car...
Status:
US Approved Rx (2014)
First approved in 2014

Class (Stereo):
CHEMICAL (ABSOLUTE)



Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R. It has been approved for the treatment of insomnia. The mechanism by which suvorexant exerts its therapeutic effect in insomnia is presumed to be through antagonism of orexi...
Status:
US Approved Rx (2022)
First approved in 2014

Class (Stereo):
CHEMICAL (ABSOLUTE)



Tasimelteon, developed by Vanda Pharmaceuticals Inc under license from Bristol-Myers Squibb Co, is a melatonin receptor agonist. Tasimelteon differs structurally from melatonin and drugs with known melatonin agonist activity, in particular by its dis...
Status:
US Approved Rx (2012)
First approved in 2011

Class (Stereo):
CHEMICAL (ACHIRAL)



Clobazam belongs to the 1,5-benzodiazepine class of drugs with antiepileptic properties. It has been used to treat anxiety and epilepsy since 1970s. In the US clobazam was approved for marketing in October of 2011 for the adjunctive treatment of seiz...
Status:
US Approved Rx (2021)
First approved in 2010

Class (Stereo):
CHEMICAL (ABSOLUTE)



Lurasidone is a novel antipsychotic agent approved for the treatment of schizophrenia in a number of countries including the UK and is also approved in the USA and Canada for the treatment of bipolar depression as either a monotherapy or adjunctive t...
Status:
US Approved Rx (2009)
First approved in 2009

Class (Stereo):
CHEMICAL (ACHIRAL)


Conditions:

Iloperidone, also known as Fanapt, Fanapta, and previously known as Zomaril, is an atypical antipsychotic for the treatment of schizophrenia. Iloperidone shows high affinity and maximal receptor occupancy for dopamine D2 receptors in the caudate nucl...
Status:
US Approved Rx (2020)
First approved in 2009

Class (Stereo):
CHEMICAL (RACEMIC)



Asenapine is an antipsychotic drug. The mechanism of action of asenapine, as with other drugs having efficacy in schizophrenia and bipolar disorder, is unknown. Asenapine exhibits high affinity for serotonin 5-HT1A, 5-HT1B, 5-HT2A, 5-HT2B, 5-HT2C, 5-...